다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Breast cancer research and treatment, v.65 no.1, 2001년, pp.77 - 85
Niezabitowski, Aleksander (Department of Tumor Pathology, Center of Oncology, Cracow , Poland) , Lackowska, Bozena (Department of Tumor Pathology, Center of Oncology, Cracow , Poland) , Rys, Janusz (Department of Tumor Pathology, Center of Oncology, Cracow , Poland) , Kruczak, Anna (Department of Tumor Pathology, Center of Oncology, Cracow , Poland) , Kowalska, Teresa (Department of Radiotherapy, Center of Oncology, Cracow , Poland) , Mitus, Jerzy (Department of Surgery, Center of Oncology, Cracow, Poland) , Reinfuss, Marian (Department of Radiotherapy, Center of Oncology, Cracow , Poland) , Markiewicz, Dorota (Department of Tumor Pathology, Center of Oncology, Cracow , Poland)
The goal of this study was the prognostic evaluation of histology, mitotic rate, S-phase fraction (SPF) and expression of proliferative antigen Ki67 and p53 protein in phyllodes tumor of the breast. The study was performed in the group of 118 patients with phyllodes tumor treated by surgery from 1952 to 1998. Mitotic rate was assessed on the representative histological specimens. Expressions of Ki67 and p53 were evaluated by immunohistochemistry on a section from the corresponding paraffin blocks which were also used for flow cytometric DNA evaluation. Histologically, 52 tumors were benign (LGM), 24 borderline malignancies (BM) while among 42 malignant tumors, 20 were monomorphous (HGM) and the remaining 22 revealed heterologic elements (HGH). Tumor recurrencies occurred in 17 patients, predominantly during the first three years after surgery, and 13 patients died of the tumor (1 BM, 12 both malignant variants). Multivariate analysis demonstrated mitotic rate, SPF and p53 expression as independent prognostic parameters for the disease-free survival. Histological tumor type and expression of Ki67 influenced independently the overall survival. In conclusion, the histological type of tumor phyllodes forms the basis for the prognosis of clinical outcome, but the indicators of the proliferative activity, especially Ki67 index, are valuable prognostic factors among patients with malignant variant of phyllodes tumor of the breast. Expression of the p53 protein in tumor cells could be also useful when the percentage of cells and intensity of expression are considered.
Histopathology RM Feakins 35 162 1999 10.1046/j.1365-2559.1999.00682.x Feakins RM, Mulcahy HE, Nickols CD, Wells CA: p53 expression in phyllodes tumours is associated with histological features of malignancy but does not predict outcome. Histopathology 35: 162-169, 1999
Cancer LJ Layfield 64 7 1486 1989 10.1002/1097-0142(19891001)64:7<1486::AID-CNCR2820640721>3.0.CO;2-7 Layfield LJ, Hart J, Neuwirth H, Bohman R, Trumbull WE, Giuliano AE: Relation between DNA ploidy and the clinical behavior of phyllodes tumor. Cancer 64(7): 1486-1489, 1989
Am J Clin Pathol AK El Naggar 93 4 480 1990 10.1093/ajcp/93.4.480 El Naggar AK, Ro JY, McLemore D, Garnsy L: DNA content and proliferative activity of cystosarcoma phyllodes of the breast. Potential prognostic significance. Am J Clin Pathol 93(4): 480-485, 1990
J Surg Oncol AK El Naggar 44 3 151 1990 10.1002/jso.2930440306 El Naggar AK, Mackay B, Sneige N, Batsakis JG: Stromal neoplasms: a comparative flow cytometric study. J Surg Oncol 44(3): 151-156, 1990
Arch Pathol LabMed MJ Palko 114 9 949 1990 Palko MJ, Wang SE, Shackney SE, Cottington EM, Levitt SB, Hartsock RJ: Flow cytometric S fraction as a predictor of clinical outcome in cystosarcoma phyllodes. Arch Pathol LabMed 114(9): 949-952, 1990
Hum Pathol PA Keelan 23 9 1048 1992 10.1016/0046-8177(92)90268-8 Keelan PA, Myers JL, Wold LE, Katzmann JA, Gibney DJ: Phyllodes tumor: clinicopathologic review of 60 patients and flow cytometric analysis in 30 patients. Hum Pathol 23(9): 1048-1054, 1992
Mod Pathol MM Grimes 5 3 232 1992 Grimes MM: Cystosarcoma phyllodes of the breast: histologic features, flow cytometric analysis and clinical correlations. Mod Pathol 5(3): 232-239, 1992
Path Res Prac L Kocova 194 1 97 1998 10.1016/S0344-0338(98)80076-9 Kocova L, Skalova A, Fakan F, Rousarova M: Phyllodes tumor of the breast: Immunohistochemical study of 37 tumours using MIB1 antibody. Path Res Prac 194(1): 97-104, 1998
Anticancer Res F Witte 19 4B 3355 1999 Witte F, Honig A, Mirecka J, Schauer A: Cystosarcoma phyllodes of the breast: prognostic significance of proliferation and apoptosis associated genes. Anticancer Res 19(4B): 3355-3359, 1999
Pathol Int Y Umekita 49 9 807 1999 10.1046/j.1440-1827.1999.00950.x Umekita Y, Yoshida H: Immunohistochemical study of MIB1 expression in phyllodes tumor and fibroadenoma. Pathol Int 49(9): 807-810, 1999
J Pathol V Kuenen Boumeester 189 2 169 1999 10.1002/(SICI)1096-9896(199910)189:2<169::AID-PATH408>3.0.CO;2-P Kuenen Boumeester V, Henzen-Logmans SC, Timmermans MM, van Staveren LL, van Gal A, Peeterse HJ, Bonnena J, Berns EM: Altered expression of p53 and its regulated proteins in phyllodes tumours of the breast. J Pathol 189(2): 169-175, 1999
Oncogene S Mayzoyer 9 4 1237 1994 Mayzoyer S, Lalle P, Moyret-Lalle C, Marcais C, Schraub S, Frappaz D, Sobol H, Ozturk M: Two germ-line mutations affecting the same nucleotide at codon 257 of p53 gene, a rare site for mutations. Oncogene 9(4): 1237-1239, 1994
Cytopathology IP Shabalova 8 3 177 1997 10.1046/j.1365-2303.1997.45875458.x Shabalova IP, Chemeris GJ, Ermilova VD, Rodionova LM, Pavlikova NA, Syrjanen KJ: Phyllodes tumour: cytologic and histologic presentation of 22 cases and imunohistochemical demonstration of p53. Cytopathology 8(3): 177-187, 1997
Niezabitowski A, Lackowska B, Kruczak A, Rys J, Reinfuss M, Mitus J, Markiewicz D: Evaluation of histology in phyllodes tumor of the breast. A study of 118 cases. Pol J Pathol (in press).
PP Rosen 155 1997 Breast Pathology Rosen PP: Breast Pathology. Lippincott-Raven Publishers, Philadelphia-New York, 1997, pp 155-172
J Histochem Cytochem DW Hedley 31 1333 1983 10.1177/31.11.6619538 Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA: Method for analysis of cellular DNA content of paraffinembedded pathological material using flow cytometry. J Histochem Cytochem 31: 1333-1335, 1983
Cytometry TW Shankey 14 472 1993 10.1002/cyto.990140503 Shankey TW, Rabinovitch PS, Bagwell B, Bauer KD, Duque RE, Hedley DW, Mayall BH, Wheeless LL: Guidelines for implementation of clinical DNA cytometry. Cytometry 14: 472-477, 1993
J Surg Oncol A Niezabitowski 70 150 1999 10.1002/(SICI)1096-9098(199903)70:3<150::AID-JSO2>3.0.CO;2-Z Niezabitowski A, Czajecki K, Rys J, Kruczak A, Gruchala A, Wasilewska A, Lackowska B, Sokolowski A, Szklarski W: Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol 70: 150-160, 1999
Dtsch Arztebl W Remmele 83 3362 1986 Remmele W, Stegner HE:Immunohistochemischer Nachweis von Ostrogenreceptoren (ERICA) inMammakarzinomgewebe Vorschlag zur einheitlichen Formulirung des Untresuchungs befundes. Dtsch Arztebl 83: 3362-3364, 1986
Histopathology CJC Moffat 27 207 1995 Moffat CJC, Pinder SE, Dixon AR, Elston CW, Blamey RW, Ellis IO: Phyllodes tumour of the breast: a clinicopathological review of thirty-two cases. Histopathology 27: 207-218, 1995
Cancer M Reinfuss 77 5 910 1996 10.1002/(SICI)1097-0142(19960301)77:5<910::AID-CNCR16>3.0.CO;2-6 Reinfuss M, Mitus J, Duda K, Stelmach A, Rys J, Smolak K: The treatment and prognosis of patients with phyllodes tumor of the breast. Cancer 77(5): 910-916, 1996
Aust NZJ Syrg DJ Holthouse 69 635 1999 10.1046/j.1440-1622.1999.01654.x Holthouse DJ, Smith PA, Naunton-Morgan R, Minchin D: Cystosarcoma phyllodes: The Western Australian experience. Aust NZJ Syrg 69: 635-638, 1999
Br J Surg WK de Roos 86 396 1999 10.1046/j.1365-2168.1999.01035.x de Roos WK, Kaye P, Dent DM: Factors leading to local recurrence or death after surgical resection of phyllodes tumours of the breast. Br J Surg 86: 396-399, 1999
Arch Gynecol Obstet J Zahner 246 3 153 1989 10.1007/BF00934076 Zahner J, Bässler R: The rate of mitosis in cystosarcoma phyllodes (phyllodes tumor WHO) of the breast. An analysis of 47 cases. Arch Gynecol Obstet 246 (3): 153-157, 1989
Arch Pathol Lab Med TM Murad 112 7 752 1988 Murad TM, Hines JR, Beal J, Bauer K: Histopathological and clinical correlations of cystosarcoma phyllodes. Arch Pathol Lab Med 112(7): 752-756, 1988
Histopathology EKA Millar 34 491 1999 10.1111/j.1365-2559.1999.00666.x Millar EKA, Beretov J, Marr P, Sarris M, Clarke RA, Kearsley JH, Lee CS: Malignant phyllodes tumors of the breast display increased stromal p53 protein expression. Histopathology 34: 491-496, 1999
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.